Intelligence Report · ~15 min read
Anesthesiology · Postoperative Nausea and Vomiting Therapeutic Area Assessment
5 signals · 1 insights · 20 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Low Confidence · 51%
Evidence
26 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Anesthesiology · Postoperative Nausea and Vomiting integrates 5 signals, 1 executive insights, and 20 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 16, 2026
Study on Perfusion Index vs Surgical Pleth Index for Pediatric Caudal Block Effectiveness
A study is underway to compare the Perfusion Index (PI) and Surgical Pleth Index (SPI) in assessing caudal block effectiveness in pediatric patients.
View detail - signalJul 7, 2026
Wrist-Ankle Acupuncture Shows Promise for Preventing Postoperative Nausea in High-Risk Patients
A randomized controlled trial evaluated the efficacy of wrist-ankle acupuncture for preventing postoperative nausea and vomiting in high-risk female patients.
View detail - signalJun 25, 2026
Trial Protocol for Liposomal Bupivacaine in Shoulder Arthroscopy Pain Management
This document outlines a randomized controlled trial protocol to evaluate different concentrations of liposomal bupivacaine in ultrasound-guided superior trunk block for postoperative analgesia in shoulder arthroscopy.
View detail - signalJun 20, 2026
Study on Liposomal Bupivacaine for Pain Management in VATS Partial Pneumonectomy
A clinical trial is evaluating the effectiveness of intercostal nerve block with liposomal bupivacaine versus conventional bupivacaine in improving postoperative recovery quality in VATS partial pneumonectomy.
View detail - regulatoryJul 16, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 16, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 16, 2026
Pediatric Tracking Requirements Under FDAAA
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
View detail - regulatoryJul 16, 2026
Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
View detail - insightJun 12, 2026
Impact of Midazolam Timing Study on Pediatric Anesthesia Practices
The ongoing clinical trial evaluating midazolam administration timing in pediatric adenotonsillectomy could reshape best practices in pediatric anesthesia. The results may lead to significant changes in clinical guidelines and impact the competitive landscape for anxiolytics in this therapeutic area. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 10 ranked evidence items (2 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 20 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
83%Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
83%Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidencePediatric Tracking Requirements Under FDAAA
72%Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
Source: FDA
View evidenceDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
72%Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
Source: FDA
View evidenceFDA AP — MALARONE PEDIATRIC (SUPPL)
72%Application NDA021078. Sponsor: GLAXOSMITHKLINE. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ATOVAQUONE, PROGUANIL HYDROCHLORIDE.
Source: FDA
View evidenceDrug Trials Snapshots: YARTEMLEA
83%YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Source: FDA
View evidenceImpact of Midazolam Timing Study on Pediatric Anesthesia Practices
51%The ongoing clinical trial evaluating midazolam administration timing in pediatric adenotonsillectomy could reshape best practices in pediatric anesthesia. The results may lead to significant changes in clinical guidelines and impact the competitive landscape for anxiolytics in this therapeutic area. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 10 ranked evidence items (2 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Study on Perfusion Index vs Surgical Pleth Index for Pediatric Caudal Block Effectiveness
Trial Update
- Wrist-Ankle Acupuncture Shows Promise for Preventing Postoperative Nausea in High-Risk Patients
Trial Update
- Trial Protocol for Liposomal Bupivacaine in Shoulder Arthroscopy Pain Management
Trial Update
- Study on Liposomal Bupivacaine for Pain Management in VATS Partial Pneumonectomy
Trial Update
- Study on Timing of Midazolam in Pediatric Adenotonsillectomy to Assess Stress and Recovery
Trial Update
Insights
- Impact of Midazolam Timing Study on Pediatric Anesthesia Practices
Anesthesiology · Pediatric Surgery